GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Endonovo Therapeutics ENDV · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Endonovo Therapeutics — daily ENDV Delayed
Market value
$13,921
Last close × shares
Volume
500k
Shares, 9 Nov 2026

About Endonovo Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Endonovo Therapeutics is based in Woodland Hills, California and is incorporated in Delaware. Its shares trade on OTC under the ticker ENDV. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2022, it reported revenue of $135,355 and a net loss of $18.5m. At that date it held total assets of $1.3m and shareholders' equity of −$32.2m. By business, Royalty [Member] brought in 83.9% of revenue, followed by Direct Sales Medical Care Providers Gross [Member] at 16.1%.

In its own words

Resources International, Inc. began operations on September 1, 2011, and was formally incorporated on October 17, 2011.

December 22, 2017, we acquired intellectual property and other assets (the “RGN Assets”) from Rio Grande Neurosciences, Inc.

Company is negotiating with a major distribution partner in order to initiate the marketing of SofPulse® in South and Central America.

(GDP) of most developed nations, health care can form an enormous part of a country’s economy.

U.S. GDP by 2025. Globally, by 2040, Healthcare spending is expected to exceed $18 Trillion annually.

SofPulse® allows patients to get back to an active life faster with less use of narcotics.

SofPulse® device is manufactured for us by ADM Tronics, Inc. in an FDA approved facility in Northvale, New Jersey.

Quoted from its 10-K, filed 17 Apr 2023. Read the filing on SEC.gov ↗

More about Endonovo Therapeutics →

How it makes its money

Revenue, year to 31 Dec 2022

  • Royalty [Member] $113,623 · 83.9%
  • Direct Sales Medical Care Providers Gross [Member] $21,732 · 16.1%

Latest on Endonovo Therapeutics

Our reporting

We have not reported on Endonovo Therapeutics yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Endonovo Therapeutics's ticker?

Endonovo Therapeutics trades as ENDV on its US listing, under ISIN US29272H3003.

What was Endonovo Therapeutics's last closing price?

0.00 on 9 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.